Pharmacy Medical News about Mucopolysaccharidosis VI

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A systematic review of new advances in the management of mucopolysaccharidosis VI: focus on galsulfase
Biologics: targets & therapy, 09/28/09

Dib RPE et al. – There is some evidence to support the use of galsulfase in the treatment of MPS VI; however due to the very low quantity of included studies the authors could not analyze it in an appropriate way. This review highlights the need for continued research into the use of enzyme replacement therapy for MPS VI.

<< Previous
Nocardithiocin, a novel thiopeptide antibiotic, produced by...

Next >>
Biological targets in the treatment of rheumatoid arthritis: a...

Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis
Oncogene, 10/29/09 Relevance Score: 43%

The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Ophthalmology, 11/03/09 Relevance Score: 42%

Adipose Tissue Collagen VI in Obesity
Journal of Clinical Endocrinology and Metabolism, 10/29/09 Relevance Score: 42%

The diagnostic dilemma of neuro-imaging in acute isolated sixth nerve palsy
Current Opinion in Ophthalmology, 10/27/09 Relevance Score: 42%

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09 Relevance Score: 40%